MR assessment of antiangiogenic therapy
抗血管生成治疗的 MR 评估
基本信息
- 批准号:6563961
- 负责人:
- 金额:$ 29.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-01-01 至 2002-12-31
- 项目状态:已结题
- 来源:
- 关键词:angiogenesis angiogenesis inhibitors antineoplastics athymic mouse bioimaging /biomedical imaging biomarker cardiovascular imaging /visualization contrast media cooperative study dosage drug administration routes drug screening /evaluation human subject magnetic resonance imaging mathematical model neoplasm /cancer blood supply pharmacokinetics vascular endothelium permeability
项目摘要
Description: (provided by applicant)
There is now considerable evidence that dynamic contrast agent-enhanced
magnetic resonance imaging (MRI) data, when analyzed with appropriate
pharmacokinetic models, are able to provide quantitative information regarding
the vascular volume fraction (fvv), permeability-surface area product (PS),
and contrast agent reflux rate (kR) in tumors. If shown to be accurate, such
non-invasive measures will be highly useful in evaluating the efficacy of
antiangiogenic therapies and in predicting how well chemotherapeutic agents
will penetrate into tumors through diffusive and convective processes.
Limited, and often contradictory, studies have been performed to date to
correlate MRI-derived in vivo measures of fvv, PS, and kR with existing "gold
standards" such as immunohistochemistry-based measures of microvessel density
and vascular permeability. Furthermore, rigorous comparisons of MRI-derived
measures obtained using FDA-approved low molecular weight contrast media with
those obtained using theoretically advantageous higher molecular weight media
currently in clinical trials are limited. Such studies are needed to establish
the limitations of using each class of contrast media in assessing fvv, PS,
and kR. These issues must be resolved prior to the application of such
promising non-invasive measures to clinical monitoring of the efficacy of
antiangiogenic therapy. The overall goals of this project are to 1)
demonstrate that accurate in vivo quantitative measures of fvv, PS, and kR can
be obtained via single and/or dual tracer pharmacokinetic modeling of dynamic
contrast agent-enhanced MRI data, and 2) correlate such measures, in both
animal models and human studies, with other surrogate markers of angiogenesis,
including expression of specific angiogenic factors, proteases, rates of
endothelial cell apoptosis, and endothelial cell-specific markers. The
specific aims in this project are: 1) correlation of single and dual tracer
pharmacokinetic measures of fvv, PS, and kR obtained using high, medium, and
low molecular weight contrast agents with immunohistochemical and radionuclide
determinations of microvessel density and vascular permeability; 2)
acquisition of longitudinal pharmacokinetic measures of fvv, PS, and kR in
subcutaneously implanted tumors treated with antiangiogenic therapies, and
correlation of these measures with other surrogate markers of angiogenesis and
vascular permeability; and 3) acquisition of longitudinal pharmacokinetic
measures in patients enrolled in clinical trials of antiangiogenic drugs, and
correlation of these measures with other invasive surrogate markers of
angiogenesis.
描述:(由申请人提供)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Edward F Jackson其他文献
Edward F Jackson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Edward F Jackson', 18)}}的其他基金
Medical Physics Training Grant for Image-Guided Therapy Research
图像引导治疗研究医学物理培训补助金
- 批准号:
7271269 - 财政年份:2006
- 资助金额:
$ 29.68万 - 项目类别:
Medical Physics Training Grant for Image-Guided Therapy Research
图像引导治疗研究医学物理培训补助金
- 批准号:
7499039 - 财政年份:2006
- 资助金额:
$ 29.68万 - 项目类别:
Medical Physics Training Grant for Image-Guided Therapy Research
图像引导治疗研究医学物理培训补助金
- 批准号:
7066892 - 财政年份:2006
- 资助金额:
$ 29.68万 - 项目类别:
Medical Physics Training Grant for Image-Guided Therapy Research
图像引导治疗研究医学物理培训补助金
- 批准号:
7906917 - 财政年份:2006
- 资助金额:
$ 29.68万 - 项目类别:
Medical Physics Training Grant for Image-Guided Therapy Research
图像引导治疗研究医学物理培训补助金
- 批准号:
7666178 - 财政年份:2006
- 资助金额:
$ 29.68万 - 项目类别:
相似海外基金
Development of Novel Lung Cancer Therapy Using Tumor-Specific Angiogenesis Inhibitors and Drug Repositioning
使用肿瘤特异性血管生成抑制剂和药物重新定位开发新型肺癌疗法
- 批准号:
21H03019 - 财政年份:2021
- 资助金额:
$ 29.68万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of biomarkers related to drug resistance of angiogenesis inhibitors
血管生成抑制剂耐药性相关生物标志物的开发
- 批准号:
20K08542 - 财政年份:2020
- 资助金额:
$ 29.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural and Functional Studies of Brain Angiogenesis Inhibitors (BAIs/ADGRBs)
脑血管生成抑制剂 (BAIs/ADGRB) 的结构和功能研究
- 批准号:
9813883 - 财政年份:2019
- 资助金额:
$ 29.68万 - 项目类别:
Elucidation of proteinuria expression mechanism by angiogenesis inhibitors and research on adverse effect avoidance
血管生成抑制剂蛋白尿表达机制的阐明及不良反应避免的研究
- 批准号:
17K08457 - 财政年份:2017
- 资助金额:
$ 29.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Evaluation of cardiotoxicity and elucidation of cardiotoxic molecular mechanisms in cancer patients receiving angiogenesis inhibitors
接受血管生成抑制剂的癌症患者的心脏毒性评估和心脏毒性分子机制的阐明
- 批准号:
26461102 - 财政年份:2014
- 资助金额:
$ 29.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Minimally invasive response evaluation in vivo for the dual therapy of the angiogenesis inhibitors
血管生成抑制剂双重治疗的体内微创疗效评价
- 批准号:
23591763 - 财政年份:2011
- 资助金额:
$ 29.68万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ANGIOGENESIS INHIBITORS IN THE MULTIMODAL TREATMENT OF PEDIATRIC SOLID TUMORS
血管生成抑制剂在小儿实体瘤多模式治疗中的应用
- 批准号:
8309814 - 财政年份:2011
- 资助金额:
$ 29.68万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
7351352 - 财政年份:2008
- 资助金额:
$ 29.68万 - 项目类别:
Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
现有药物中新型血管生成抑制剂的发现和研究
- 批准号:
8002099 - 财政年份:2008
- 资助金额:
$ 29.68万 - 项目类别:
Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
针对炭疽毒素受体的新型血管生成抑制剂
- 批准号:
7615664 - 财政年份:2008
- 资助金额:
$ 29.68万 - 项目类别: